Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2016 Aug;20(4):511-535.
doi: 10.1007/s10157-015-1223-y.

Evidence-based clinical practice guidelines for IgA nephropathy 2014

Yukio Yuzawa  1 , Ryohei Yamamoto  2 , Kazuo Takahashi  3 , Ritsuko Katafuchi  4 , Makoto Tomita  3 , Yoshihide Fujigaki  5 , Hiroshi Kitamura  6 , Masashi Goto  7 , Takashi Yasuda  8 , Mitsuhiro Sato  9 , Maki Urushihara  10 , Shuji Kondo  10 , Shoji Kagami  10 , Yoshinari Yasuda  11 , Hiroyuki Komatsu  12 , Miki Takahara  13 , Yasuaki Harabuchi  13 , Kenjiro Kimura  14 , Seiichi Matsuo  11
Affiliations
Practice Guideline

Evidence-based clinical practice guidelines for IgA nephropathy 2014

Yukio Yuzawa et al. Clin Exp Nephrol. 2016 Aug.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The summary of randomized controlled trials of corticosteroids and immunosuppressive agents in adult patients with IgAN
Fig. 1
Fig. 1
The summary of randomized controlled trials of corticosteroids and immunosuppressive agents in adult patients with IgAN
Fig. 2
Fig. 2
The summary of randomized controlled trials of RAS blockers, antiplatelet agents, and fish oils in adult patients with IgAN
Fig. 2
Fig. 2
The summary of randomized controlled trials of RAS blockers, antiplatelet agents, and fish oils in adult patients with IgAN
Fig. 3
Fig. 3
An outline of treatment of IgAN in adults with a focus on prevention of renal dysfunction (based on randomized controlled trials for IgAN) This figure shows the indications for treatment intervention, based mainly on the results (Figs. 1, 2) of RCTs, often focusing on renal function and amount of urinary protein excreted as patient inclusion/exclusion criteria. In actual clinical practice, besides renal function and urinary protein level, other factors such as renal histopathological findings and age should also be considered to carefully decide the indications for these treatment interventions. Others *: Tonsillectomy (combined with high-dose pulse corticosteroid therapy) and therapy with non-steroidal immunosuppressive agents, antiplatelet agents, and n-3 fatty acids (fish oil). CKD management guidelines **: The Japanese Society of Nephrology Evidence based Clinical Practice Guideline for CKD 2013: Hypertension (Chap. 4), salt intake (Chaps. 3, 4), lipid disorders (Chap. 14), glucose intolerance (Chap. 9), obesity (Chap. 15), smoking (Chap. 2), anemia (Chap. 7), CKD mineral and bone disorders (CKD-MBD, Chap. 8), and metabolic acidosis (Chap. 3) should also be managed as necessary
See this image and copyright information in PMC

Publication types

MeSH terms

LinkOut - more resources